DK2660600T3 - Diagnostisk lægemiddel og diagnostisk fremgangsmåde for alzheimer¿s sygdom - Google Patents

Diagnostisk lægemiddel og diagnostisk fremgangsmåde for alzheimer¿s sygdom Download PDF

Info

Publication number
DK2660600T3
DK2660600T3 DK11853134.2T DK11853134T DK2660600T3 DK 2660600 T3 DK2660600 T3 DK 2660600T3 DK 11853134 T DK11853134 T DK 11853134T DK 2660600 T3 DK2660600 T3 DK 2660600T3
Authority
DK
Denmark
Prior art keywords
gly
ala
leu
pro
s38aa
Prior art date
Application number
DK11853134.2T
Other languages
English (en)
Inventor
Lars O Tjernberg
Bengt Winblad
Masakazu Hashimoto
Mikio Aoki
Hiroyuki Nakagawa
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Application granted granted Critical
Publication of DK2660600T3 publication Critical patent/DK2660600T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (13)

1. Anvendelse af et anti-S38AA-antistof til bestemmelse af Alzheimers sygdom in vitro eller ex vivo.
2. Fremgangsmåde til bestemmelse af Alzheimers sygdom hos et dyr, hvilken fremgangsmåde omfatter at påvise et S38AA-fragment i en prøve indhentet fra nævnte dyr.
3. Fremgangsmåde ifølge krav 2, hvor dyret er et menneske.
4. Fremgangsmåde ifølge krav 2 eller 3, hvor S38AA-fragmentet er et fragment afledt af S38AA isoform 1.
5. Fremgangsmåde ifølge krav 2 eller 3, hvor S38AA-fragmentet er et polypeptid omfattende en aminosyresekvens vist ved SEQ ID NO: 3.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 5, hvor prøven er blod, cerebrospinalvæske eller urin.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 5, hvor prøven er cerebrospinalvæske.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 5, hvor prøven er blod.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 5, hvor prøven er plasma.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 2 til 9, yderligere omfattende at påvise en eller flere andre diagnostiske markører for Alzheimers sygdom.
11. Fremgangsmåde til søgning efter et kandidatstoftil behandling eller forebyggelse af Alzheimers sygdom, hvilken fremgangsmåde indeholder følgende trin: (1) at bringe et teststof i kontakt med en celle, således at måling af produktion af et S38AA-fragment tillades; (2) at måle produktionsmængden af S38AA-fragmentet i cellen, der er bragt i kontakt med teststoffet, og at sammenligne produktionsmængden med S38AA-fragmentets ditto i en kontrolcelle fri for kontakt med teststoffet; og (3) at udvælge et teststof, som nedregulerer produktionsmængden af S38AA-fragmentet, som et kandidatstof til behandling eller forebyggelse af Alzheimers sygdom, baseret på sammenligningsresultaterne fra ovennævnte (2).
12. Fremgangsmåde ifølge krav 4, hvor S38AA isoform 1 er et polypeptid blandt følgende (a) eller (b): (a) et polypeptid omfattende en aminosyresekvens vist i SEQ ID NO: 2, eller (b) et polypeptid omfattende en aminosyresekvens, der har mindst 95% identitet med aminosyresekvensen vist i SEQ ID NO: 2.
13. Fremgangsmåde ifølge krav 5, hvor S38AA-fragmentet er et polypeptid omfattende den 505. - 1014. aminosyre i sekvensen vist i SEQ ID NO: 2.
DK11853134.2T 2010-12-28 2011-12-28 Diagnostisk lægemiddel og diagnostisk fremgangsmåde for alzheimer¿s sygdom DK2660600T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010293891 2010-12-28
PCT/JP2011/080517 WO2012091138A1 (ja) 2010-12-28 2011-12-28 アルツハイマー病の診断薬及び診断方法

Publications (1)

Publication Number Publication Date
DK2660600T3 true DK2660600T3 (da) 2018-11-26

Family

ID=46383225

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11853134.2T DK2660600T3 (da) 2010-12-28 2011-12-28 Diagnostisk lægemiddel og diagnostisk fremgangsmåde for alzheimer¿s sygdom

Country Status (9)

Country Link
US (2) US10393757B2 (da)
EP (1) EP2660600B1 (da)
JP (1) JP5894085B2 (da)
KR (1) KR101883515B1 (da)
CN (2) CN105548561B (da)
CA (1) CA2823286C (da)
DK (1) DK2660600T3 (da)
ES (1) ES2689753T3 (da)
WO (1) WO2012091138A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
AU2019318888A1 (en) 2018-08-07 2021-03-18 Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN112946300A (zh) * 2021-03-19 2021-06-11 苏冬梅 基于“Western Blot”法的阿尔茨海默病早期检测试剂盒及其制备方法
CN113820497B (zh) * 2021-09-23 2024-11-01 中国科学技术大学 衰老胶质细胞相关的生物标志物及其用于阿尔茨海默症诊断的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
CA2420902A1 (en) 2000-08-28 2002-03-07 Craig A. Rosen 18 human secreted proteins
JP2005503790A (ja) 2001-08-17 2005-02-10 インサイト・ゲノミックス・インコーポレイテッド 輸送体及びイオンチャネル
EP1885887A1 (en) * 2005-06-01 2008-02-13 EVOTEC Neurosciences GmbH Diagnostic and therapeutic target slc39a11 proteins for neurodegenerative diseases
EP1891234B1 (en) * 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
JP2008184387A (ja) * 2007-01-26 2008-08-14 Shiseido Co Ltd Ａｄａｍ阻害剤
WO2009048747A2 (en) * 2007-10-08 2009-04-16 Indiana University Research And Technology Corporation Candidate genes and blood biomarkers for bipolar mood disorder, alcoholism and stress disorder
EP2924112A1 (en) * 2009-02-02 2015-09-30 Chromocell Corporation Novel cell lines and methods
WO2010140694A1 (ja) * 2009-06-04 2010-12-09 大日本住友製薬株式会社 アミロイドベータペプチドの産生を促進する因子を用いた阻害剤のスクリーニング方法及びそれによって得られる阻害剤

Also Published As

Publication number Publication date
CN105548561A (zh) 2016-05-04
CN103370620B (zh) 2016-01-20
CA2823286A1 (en) 2012-07-05
CN105548561B (zh) 2021-12-21
WO2012091138A1 (ja) 2012-07-05
JP5894085B2 (ja) 2016-03-23
US10393757B2 (en) 2019-08-27
CA2823286C (en) 2020-01-28
US20130280732A1 (en) 2013-10-24
EP2660600B1 (en) 2018-08-08
KR20140004701A (ko) 2014-01-13
EP2660600A1 (en) 2013-11-06
US20190369124A1 (en) 2019-12-05
CN103370620A (zh) 2013-10-23
ES2689753T3 (es) 2018-11-15
EP2660600A4 (en) 2015-05-06
JPWO2012091138A1 (ja) 2014-06-09
KR101883515B1 (ko) 2018-07-30

Similar Documents

Publication Publication Date Title
US20190369124A1 (en) Diagnostic drug and diagnostic method for alzheimer's disease
US9448232B2 (en) Methods and materials for detecting C9ORF72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or C9ORF72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis
US8105839B2 (en) Diagnostic kit for Alzheimer's disease, diagnostic marker, and detection method for indicator of pathological state thereof
US20120052592A9 (en) Method for determining prognosis of acute central nervous system disorder
US8354236B2 (en) Detection of neurodegenerative disease
JP7654126B2 (ja) アルツハイマー病の判定薬および判定方法
DK2389587T3 (da) Diagnostiske og prognostiske fremgangsmåder relateret Alzheimers sygdom
WO2021157634A1 (ja) タウオパチーおよび認知症関連疾患の判定薬および判定方法
JP2005539228A (ja) 軽度の認知障害を示すアルツハイマー患者特有の診断方法
HK1187404B (en) Diagnostic drug and diagnostic method for alzheimer's disease
HK1187404A (en) Diagnostic drug and diagnostic method for alzheimer's disease
JP2021060289A (ja) 細胞内コレステロールレベルに関連する疾患の、診断用マーカー、診断を補助する方法、診断のためにデータを収集する方法、罹患可能性を評価する方法、及び診断用キット
EP3903107B1 (en) Method for detecting the presence and quantity of the lrp8 receptor and of its proteolytic fragments, detection kit and related antibodies
JP6908810B2 (ja) ４リピートタウの質的違いを検出する特異的結合試薬、これを用いた検査方法、検査キット、及び医薬のスクリーニング方法
HK40048565A (en) Diagnostic drug and diagnostic method for alzheimer's disease